A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2‐Negative Breast Cancer

LESSONS LEARNED: The combination of eribulin with 5‐fluorouracil, either doxorubicin or epirubicin, and cyclophosphamide (FAC/FEC) was not superior to the combination of paclitaxel with FAC/FEC and was associated with greater hematologic toxicity. Eribulin followed by an anthracycline‐based regimen...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Bora, Song, Juhee, Ibrahim, Nuhad K., Koenig, Kimberly B., Chavez‐MacGregor, Mariana, Ensor, Joe E., Gomez, Jill Schwartz, Krishnamurthy, Savitri, Caudle, Abigail S., Shaitelman, Simona F., Whitman, Gary J., Valero, Vicente
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873313/
https://www.ncbi.nlm.nih.gov/pubmed/33140515
http://dx.doi.org/10.1002/onco.13581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873313/
https://www.ncbi.nlm.nih.gov/pubmed/33140515
http://dx.doi.org/10.1002/onco.13581

Ejemplares similares